DE69527805T2 - Chemische mittel - Google Patents

Chemische mittel

Info

Publication number
DE69527805T2
DE69527805T2 DE69527805T DE69527805T DE69527805T2 DE 69527805 T2 DE69527805 T2 DE 69527805T2 DE 69527805 T DE69527805 T DE 69527805T DE 69527805 T DE69527805 T DE 69527805T DE 69527805 T2 DE69527805 T2 DE 69527805T2
Authority
DE
Germany
Prior art keywords
enzyme
dna
prodrug
mutated
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69527805T
Other languages
German (de)
English (en)
Other versions
DE69527805D1 (de
Inventor
Charles Blakey
Thomas Boyle
Huw Davies
Johannes Eggelte
William Heaton
Frederick Hennam
Francois Hennequin
Robert Marsham
Robert Rabin
Michael Slater
Antonio Tarragona-Fiol
Christopher John Taylorson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Biotechnology Ltd
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69527805(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69527805D1 publication Critical patent/DE69527805D1/de
Application granted granted Critical
Publication of DE69527805T2 publication Critical patent/DE69527805T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
DE69527805T 1994-12-23 1995-12-21 Chemische mittel Expired - Lifetime DE69527805T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (2)

Publication Number Publication Date
DE69527805D1 DE69527805D1 (de) 2002-09-19
DE69527805T2 true DE69527805T2 (de) 2003-04-24

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527805T Expired - Lifetime DE69527805T2 (de) 1994-12-23 1995-12-21 Chemische mittel

Country Status (23)

Country Link
US (1) US5985281A (https=)
EP (1) EP0806964B1 (https=)
JP (1) JP3805365B2 (https=)
KR (1) KR100270650B1 (https=)
CN (1) CN1095677C (https=)
AT (1) ATE222124T1 (https=)
AU (1) AU701916B2 (https=)
BR (1) BR9510490B1 (https=)
CA (1) CA2205091A1 (https=)
CZ (1) CZ195297A3 (https=)
DE (1) DE69527805T2 (https=)
ES (1) ES2181805T3 (https=)
FI (1) FI972683L (https=)
HU (1) HUT77450A (https=)
IL (1) IL116511A0 (https=)
MX (1) MX9704575A (https=)
NO (1) NO972882L (https=)
NZ (1) NZ297529A (https=)
PL (1) PL184031B1 (https=)
RU (1) RU2189251C2 (https=)
SK (1) SK80997A3 (https=)
TR (1) TR199501654A2 (https=)
WO (1) WO1996020011A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1193278A (zh) 1995-08-16 1998-09-16 曾尼卡有限公司 化合物
SG71046A1 (en) 1996-10-10 2000-03-21 Connector Systems Tech Nv High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
EP1220864A4 (en) * 1999-09-17 2003-05-21 Genzyme Transgenics Corp TRANSGENICALLY PRODUCED FUSION PROTEINS
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
EP2077991B1 (en) * 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) * 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU674137B2 (en) * 1992-01-30 1996-12-12 Genzyme Limited Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
JP3805365B2 (ja) 2006-08-02
RU2189251C2 (ru) 2002-09-20
IL116511A0 (en) 1996-07-23
HUT77450A (hu) 1998-04-28
CZ195297A3 (en) 1997-12-17
US5985281A (en) 1999-11-16
AU701916B2 (en) 1999-02-11
PL184031B1 (pl) 2002-08-30
JPH10511547A (ja) 1998-11-10
MX9704575A (es) 1997-10-31
NO972882D0 (no) 1997-06-20
FI972683A0 (fi) 1997-06-19
FI972683A7 (fi) 1997-06-19
KR100270650B1 (ko) 2000-11-01
PL320964A1 (en) 1997-11-24
TR199501654A2 (tr) 1996-07-21
NO972882L (no) 1997-08-19
ATE222124T1 (de) 2002-08-15
WO1996020011A1 (en) 1996-07-04
FI972683L (fi) 1997-06-19
BR9510490B1 (pt) 2010-10-05
ES2181805T3 (es) 2003-03-01
CA2205091A1 (en) 1996-07-04
CN1095677C (zh) 2002-12-11
DE69527805D1 (de) 2002-09-19
BR9510490A (pt) 1998-01-13
TR199501654A3 (https=) 1996-07-21
NZ297529A (en) 1999-07-29
EP0806964B1 (en) 2002-08-14
CN1171054A (zh) 1998-01-21
AU4269796A (en) 1996-07-19
SK80997A3 (en) 1998-02-04
EP0806964A1 (en) 1997-11-19

Similar Documents

Publication Publication Date Title
DE69527805T2 (de) Chemische mittel
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
JP5150103B2 (ja) 組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質
KR930006757B1 (ko) 종양세포에 세포독성물질의 전달시 전구약물과 배합되는 항체-효소 결합체
TWI781327B (zh) 葉酸受體１抗體類和免疫共軛物類及彼等之用途
EP2046375B1 (en) Methods and compositions for the selective activation of protoxins through combinatorial targeting
DE69514234T2 (de) Oberflächenlokalisierte expression von enzymen in gengesteuerter prodrugtherapie
DE69433563T2 (de) Gegen das ca55.1 antigen gerichtete bindende strukturen
US20040052793A1 (en) Caspase activivated prodrugs therapy
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
KR20220124762A (ko) 펩티드 함유 링커를 갖는 부위 특이적 항체-약물 접합체
US6436691B1 (en) Chemical compounds
JP2000504218A (ja) リガンド指令酵素プロドラッグ療法
ES2241268T3 (es) Onconasa recombinante y proteinas de fusion de onconasa recombinante.
DE69225035T2 (de) Konjugate
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: LONDON BIOTECHNOLOGY LTD., LONDON, GB